LYTIX BIOPHARMA AS - NEW SHARE CAPITAL REGISTERED

13 May 2024 15:15 CEST

Oslo, Norway, 13 May 2024: Reference is made to the stock exchange announcements
published by Lytix Biopharma AS ("Lytix" or the "Company") on 25 April 2024 and
26 April 2024 regarding the issuance of a total of 9,541,984 shares (the "Offer
Shares") by the Company's extraordinary general meeting and the board of
directors pursuant to a board authorization relating to a partially guaranteed
share offering (the "Offering").

The share capital increases relating to the Offering have today been registered
with the Norwegian Register of Business Enterprises. The Company's new share
capital is NOK 4,961,030.30, divided into 49,610,303 shares, each with a par
value of NOK 0.10.

The Offer Shares are expected to be registered in the Norwegian Central
Securities Depository (VPS) today, or tomorrow, 14 May 2024.

Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company's
continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com


About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

More information:
Access the news on Oslo Bors NewsWeb site